Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Development of advanced cell therapies using hematopoietic stem cells

S. Karlsson Group

Our research

We are studying the regulation of hematopoietic stem cells (HSCs) in order to understand how signaling pathways, transcriptional mechanisms and epigenetic regulators govern stem cell behavior to determine stem cell fate options.

Integrative signaling and transcriptional networks act in concert to determine whether hematopoietic stem cells remain quiescent, proliferate and self-renew, expand through self-renewal, differentiate or undergo apoptosis.

 

Aims

  •     Expand stem cells in vivo and ex vivo.
  •     Understand the pathogenesis of blood malignancies and genetic disorders of the blood system.
  •     Develop cell and gene therapies for these disorders.

 

Impact

Stem cell therapy is a growing therapeutic modality for serious genetic disorders and malignancies because of the difficulties in treating these diseases with conventional small molecule pharmaceuticals. Although increasing knowledge about the regulatory pathways that govern stem cell fate may lead to the discovery of small molecule drugs that can be used to expand stem cells or treat leukemia, the main therapy that is currently working in the clinic to treat serious blood disorders is blood and marrow transplantation (BMT). The most frequent candidate diseases for BMT are malignant blood disorders, particularly leukemia and lymphoma.

We are studying the regulation of hematopoietic stemcells in order to explore and develop methods to expand hematopoietic stem cells prior to transplantation to improve engraftment and the efficacy of the transplant therapy. Similarly, we are developing gene therapy for two inherited blood disorders, Diamond Blackfan anemia, a bone marrow failure disorder, and Gaucher disease, a lysosomal storage disorders affecting mostly macrophages.

 

List of Team S. Karlsson's publications


Team

(name linked to profile in Lund University research portal)

Stefan Karlsson 

Principal Investigator, Stefan [dot] Karlsson [at] med [dot] lu [dot] se

Yang Liu 

Postdoc, Yang [dot] Liu [at] med [dot] lu [dot] se 

Sarah Warsi 

PhD student, Sarah [dot] Warsi [at] med [dot] lu [dot] se 

STEFAN KARLSSON

 

Stefan Karlsson

Principal Investigator
PhD, MD, Professor
Division of Molecular Medicine & Gene Therapy
Department of Laboratory Medicine
Lund Stem Cell Center
BMC A12, Lund University
221 84 Lund, Sweden

Phone: + 46 46 222 05 77
Mail:Stefan [dot] Karlsson [at] med [dot] lu [dot] se

Profile in Lund University research portal